Dolores Baksh, Ph.D., has been appointed as the Chief Executive Officer of Applied StemCell (ASC), where she will lead the company’s next phase of growth in genome engineering. Based in California, she will focus on expanding ASC’s commercial reach, accelerating product innovation, and strengthening strategic partnerships to advance next-generation cell and gene therapies.
With more than two decades of leadership experience in biotechnology and cell and gene therapy, Dr. Baksh brings a wealth of expertise in scaling organizations, driving business strategy, and fostering innovation. Prior to joining ASC, she co-founded and served as CEO of Hyperius Biotech, where she played a pivotal role in catalyzing healthcare innovation and shaping the future of cell and gene therapy. She also held leadership positions as CEO of TAAV Biomanufacturing Solutions, Vice President at Akron Bio, and Global Cell & Gene Therapy Franchise Marketing Leader at Cytiva.
Her extensive background includes senior leadership roles at GE Healthcare, where she was recognized with the “Women in Technology Award,” and at Vineti, Organogenesis, and the National Institutes of Health. Throughout her career, Dr. Baksh has successfully driven product launches, M&A initiatives, and global commercialization strategies, making her a respected leader in the biomanufacturing and gene therapy industries.
Dr. Baksh’s appointment marks a significant milestone for Applied StemCell as it continues to position itself at the forefront of genome engineering and therapeutic innovation. Her vision and proven track record of strategic leadership will be instrumental in guiding ASC toward new opportunities that push the boundaries of science and transform patient outcomes.